Loading…
Hosted by Rahul Banerjee, MD · 🇺🇸 US · EN · 87 episodes
Established thought leaders with verified media credentials.
Blood Cancers Today brings you The HemOnc Pulse, a podcast hosted by Rahul Banerjee, MD with HemOnc Pulse Live! hosts Naval G. Daver, MD and Mehdi H. Hamadani, MD covering all topics in the world of hematologic oncology.
Rahul Banerjee, MD hosts The HemOnc Pulse, a science show with 87 episodes published.
In this Editor’s Special episode of The HemOnc Pulse, MD Anderson Cancer Center’s Naval Daver, MD, and Naveen Pemmaraju, MD, discuss MDS/MPN overlap conditions and research examining combination therapy with ruxolitinib
How can bispecific antibodies be safely delivered outside the hospital? Rahul Banerjee, MD and Ajay Nooka, MD discuss outpatient step-up dosing, prophylactic tocilizumab, CRS management, and practical tips for implementi
In this episode of HemOnc Pulse, host Dr. Rahul Banerjee of Fred Hutchinson Cancer Center sits down with Dr. Gary Simmons, a hematologist-oncologist at Virginia Oncology Associates, to explore the evolving role of commun
Learn how new approaches in allogeneic transplants, from PTCy to innovative regimens, are helping reduce GVHD and improve patient outcomes with special guest Sagar S. Patel, MD of University of Utah Health.
In this Editor’s Special Episode of The HemOncPulse, a conversation with Nicholas Richardson, DO, MPH, vice president of clinical development at Precision for Medicine, focuses on the evolving regulatory role of measurab
In this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses
This Editor’s Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regim
Dr. Eunice Wang joins host Rahul Banerjee, MD, for a clinician-focused discussion on AML, treatment complexity, and real-world leukemia management in today’s evolving therapeutic landscape.
In this episode of The HemOnc Pulse, host Melissa speaks with Omar Nadeem, MD, Senior Physician at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, about emerging genomic insigh
Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.
Dr. Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety
Host Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.
MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.
William Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today
In this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding
A panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigm
Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
During a session at The HemOnc Pulse Live! moderated by Naval Daver, MD, Eunice Wang, MD presents new insights in acute myeloid leukemia care, joined by Aditi Shastri, MBBS, Tapan Kadiya, MD, and Kelly Chien, MD for a ri
Drs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.
In this Editor’s Special of The HemOnc Pulse, Tycel Phillips, MD, joins an editor of Blood Cancers Today to break down the latest research in B-cell non-Hodgkin lymphoma presented at the 2025 ASCO Annual Meeting. The con
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch The HemOnc Pulse, visit https://hemoncpulse.podbean.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
The HemOnc Pulse is hosted by Rahul Banerjee, MD. The show is categorised under science and has published 87 episodes.
The HemOnc Pulse has published 87 episodes.
The HemOnc Pulse regularly covers science. It sits in the science category.
The HemOnc Pulse is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The HemOnc Pulse hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The HemOnc Pulse average 366 minutes, giving guests a long-form format with plenty of time to expand on their expertise.
Our data rates The HemOnc Pulse's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 3 days ago.